fondazionemichelangelo org 2024 07 03 long term Long term survival data from DESTINY Breast03 trial Jul 3 2024 Median progression free survival was 29 versus 7 2 months the 36 month progression free survival rate was 45 7 versus 12 4 and median overall survival was 52 6 versus
DESTINY Breast03 reports longest OS in previously treated www mims com singapore news updates topic destiny breast03 reports longest os in previously treated her2 positive mbc
The Lancet journals lancet Trastuzumab deruxtecan versus trastuzumab emtansine in Jan 14 2023 The second overall survival interim analysis of DESTINY Breast03 evaluates whether overall survival is improved with trastuzumab deruxtecan versus trastuzumab emtansine
Nature articles s41591 024 03021 7 Trastuzumab deruxtecan versus trastuzumab emtansine in HER2 Jun 2 2024 Trastuzumab deruxtecan T DXd demonstrated significantly improved efficacy over trastuzumab emtansine T DM1 in DESTINY Breast03 median follow up 28 months We
PubMed 36495879 Trastuzumab deruxtecan versus trastuzumab emtansine in Jan 14 2023 Background An improvement in progression free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2 positive metastatic
52 6 months Long term follow up of the DESTINY Breast03 trial has reported a median overall survival OS of 52 6 months with trastuzumab deruxtecan T DXd representing the longest reported OS in previously treated HER2 positive metastatic breast cancer mBC to date
Destiny Breast 03 Overall Survival
The ASCO Post news january 2023 Updated Results of DESTINY Breast03 T DXd vs T DM1 for Jan 26 2023 T DXd showed a significant improvement in overall survival vs T DM1 in patients with HER2 positive metastatic breast cancer as well as the longest reported median
ESMO Open article S2059 7029 24 00692 6 Trastuzumab deruxtecan versus trastuzumab emtansine in HER2 Apr 24 2024 DESTINY Breast03 is a randomized multicenter open label phase III study of trastuzumab deruxtecan T DXd versus trastuzumab emtansine T DM1 in patients with human
Destiny Breast 03 Overall Survival
MIMS singapore news updates DESTINY Breast03 reports longest OS in previously treated Jul 12 2024 Long term follow up of the DESTINY Breast03 trial has reported a median overall survival OS of 52 6 months with trastuzumab deruxtecan T DXd representing the longest
AstraZeneca media centre press releases Enhertu achieved statistically significant overall survival Dec 7 2022 Updated results from the DESTINY Breast03 Phase III trial showed that Enhertu trastuzumab deruxtecan demonstrated a statistically significant and clinically meaningful
ASCO Publications doi 10 Trastuzumab deruxtecan T DXd vs trastuzumab emtansine T May 29 2024 Background DESTINY Breast03 NCT03529110 a randomized multicenter open label phase 3 study assessed the efficacy and safety of T DXd vs T DM1 in pts with HER2 mBC
The ASCO Post issues march 25 2023 DESTINY Breast03 T DXd Improves Overall Survival vs T DM1 in Mar 25 2023 The investigators concluded T DXd showed a significant improvement in overall survival versus T DM1 in patients with HER2 positive metastatic breast cancer as well